Protalix BioTherapeutics

Update in progress

PLX (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Protalix BioTherapeutics is a biopharmaceutical company that develops, manufactures, and commercializes recombinant therapeutic proteins using its ProCellEx plant cell-based expression system. It offers Elelyso for Gaucher disease and Elfabrio for Fabry disease. It is developing PRX-115 (plant-produced PEGylated uricase) for gout and PRX-119 (PEGylated DNase I) for neutrophil extracellular trap diseases. Headquartered in Hackensack, NJ, it partners with Pfizer, Fundação Oswaldo Cruz, Chiesi, and Secarna.

Company score

Sentiment: 0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.47; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.18; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.33; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive